Transcription Factor Avian Erythroblastosis Virus E26 Oncogen Homolog-1 Is a Novel Mediator of Renal Injury in Salt-Sensitive Hypertension

Wenguang Feng, Phillip Chumley, Minolfa C. Prieto, Kayoko Miyada, Dale M. Seth, Huma Fatima, Ping Hua, Gabriel Rezonzew, Paul W. Sanders, Edgar A. Jaimes

Abstract—Transcription factor E26 transformation-specific sequence-1 (ETS-1) is a transcription factor that regulates the expression of a variety of genes, including growth factors, chemokines, and adhesion molecules. We recently demonstrated that angiotensin II increases the glomerular expression of ETS-1 and that blockade of ETS-1 ameliorates the profibrotic and proinflammatory effects of angiotensin II. The Dahl salt-sensitive rat is a paradigm of salt-sensitive hypertension associated with local activation of the renin–angiotensin system. In these studies, we determined whether: (1) salt-sensitive hypertension is associated with renal expression of ETS-1 and (2) ETS-1 participates in the development of end-organ injury in salt-sensitive hypertension. Dahl salt-sensitive rats were fed a normal-salt diet (0.5% NaCl diet) or a high-salt diet (4% NaCl) for 4 weeks. Separate groups on high-salt diet received an ETS-1 dominant-negative peptide (10 mg/kg/d), an inactive ETS-1 mutant peptide (10 mg/kg/d), the angiotensin II type 1 receptor blocker candesartan (10 mg/kg/d), or the combination high-salt diet/dominant-negative peptide/angiotensin II type 1 receptor blocker for 4 weeks. High-salt diet rats had a significant increase in the glomerular expression of the phosphorylated ETS-1 that was prevented by angiotensin II type 1 receptor blocker. ETS-1 blockade reduced proteinuria, glomerular injury score, fibronectin expression, urinary transforming growth factor-β excretion, and macrophage infiltration. Angiotensin II type 1 receptor blocker reduced proteinuria, glomerular injury score, and macrophage infiltration, whereas concomitant ETS-1 blockade and angiotensin II type 1 receptor blocker had additive effects and reduced interstitial fibrosis. Our studies demonstrated that salt-sensitive hypertension results in increased glomerular expression of phosphorylated ETS-1 and suggested that ETS-1 plays an important role in the pathogenesis of end-organ injury in salt-sensitive hypertension. (Hypertension. 2015;65:00-00. DOI: 10.1161/HYPERTENSIONAHA.114.04533.)

Key Words: angiotensins ■ Dahl salt-sensitive rats ■ hypertension ■ kidney

Salt-sensitive (SS) hypertension is a type of hypertension that affects over 50% of humans1 and is associated with a significant risk for the development of hypertensive end-organ damage, including atherosclerosis, left ventricular hypertrophy, and renal injury.2 We and others have shown that salt-sensitive hypertension is characterized by reduced cardiovascular and renal nitric oxide bioavailability and local upregulation of the renin–angiotensin system (RAS).2

Angiotensin II (Ang II) produced as result of intrarenal RAS activation is implicated in the pathogenesis of hypertensive nephrosclerosis and vascular injury by promoting oxidative stress, extracellular matrix deposition, inflammation, and cell proliferation.3–5 However, it is not clear whether these effects occur via independent mechanisms or, alternatively, via common transcriptional mechanisms that mediate the activation of multiple pathways involved in inflammation and fibrosis.

The transcription factor E26 transformation-specific sequence-1 (ETS-1) has been identified as a critical molecule that regulates the vascular expression of a variety of genes, including growth factors, chemokines, and adhesion molecules.6,7 The systemic administration of Ang II results in increased recruitment of inflammatory cells in the vasculature that is markedly reduced in ETS-1 deficient mice7 and associated with reductions in medial hypertrophy.7 Other studies have shown that ETS-1 is induced in the vasculature in response to a variety of stimuli, including Ang II,7 platelet-derived growth factor,8 thrombin,9 interleukin-1,10 and tumor necrosis factor.11

In previous studies, we demonstrated that Ang II increases the expression of ETS-1 via the increased generation of reactive oxygen species and that ETS-1 is required for the production of fibronectin in rat mesangial cells.12 In addition, we demonstrated that ETS-1 is up-regulated in the renal cortex after the systemic chronic administration of Ang II and that blockade of ETS-1 using a specific ETS-1 dominant-negative peptide (DN) reduces the renal profibrotic and proinflammatory effects of Ang II.13
Given the large body of experimental evidence demonstrating local activation of RAS in hypertensive Dahl salt-sensitive (DS) rats, we designed a series of experiments aimed at testing the hypothesis that ETS-1 is up-regulated in salt-sensitive hypertension and that ETS-1 plays a major role as mediator of renal injury in this model of hypertension. In addition, we determined the effects of ETS-1 blockade on renal injury and intrarenal RAS activation expression and the effects of combined RAS and ETS-1 blockade on renal injury in this model of hypertension.

Methods

Experimental Groups
Eight-week-old Dahl/Rapp DS male rats were purchased from Harlan (Indianapolis, IN) and maintained under controlled conditions of light, temperature, and humidity. The animals were housed in facilities accredited by the American Association for Accreditation of Laboratory Animal Care. The Institutional Animal Care and Use Sub-Committee at the University of Alabama at Birmingham approved these studies. After 2 weeks of acclimation to the new environment, the rats were divided into 6 groups (n=6 per group) and treated for 4 weeks as follows: normal salt, fed 0.5%, NaCl diet; high salt (HS), fed 4% NaCl diet; HS/DN, fed 4% NaCl diet plus ETS-1 DN (DN, 10 mg/kg/d subcutaneous by osmotic mini pump, Alzet, Cupertino, CA); HS/MU, fed 4% NaCl diet plus ETS-1 mutant peptide (MU, 10 mg/kg/d subcutaneous by osmotic mini pump); HS/angiotensin II receptor 1 blocker (ARB), fed 4% NaCl diet plus the ARB candesartan (10 mg/kg/d in the drinking water); and HS/ARB/DN, fed 4% NaCl diet plus candesartan and ETS-1 DN. Blood pressure was measured by radio telemetry as we have previously described. Before euthanasia, the rats were placed in metabolic cages for 16 hours and urine collected for 24-hour collection (Cayman, Ann Arbor, MI).

Western Blot
Western blot analysis was performed as previously described. Briefly, 100 mg of kidney cortex was homogenized in 500 µl lysis buffer (Pro# 78510, Thermo Scientific, Rockford, IL). The resulting lysates were centrifuged for 30 minutes at 10,000 g at 4°C, the supernatants collected and protein concentration quantitated by Bio-Rad assay. For immunoblotting, 30 µg of protein was separated by SDS-PAGE (10 or 15% acrylamide gel) and transferred to a polyvinylidene fluoride membrane. The blots were incubated with the primary antibodies against ETS-1 (sc-350, Santa Cruz), phospho-ETS-1(T38; 44-1104G, Invitrogen), and Fibronectin (F3648, Sigma) at 4°C for 24 hours. The blots were washed and incubated with the appropriate secondary antibodies and the signal detected by luminol chemiluminescence.

Immunofluorescence
Five-micrometer-thick kidney sections were prepared from paraffin-embedded tissues. After deparaffinization and antigen retrieval, the sections were rinsed in phosphate-buffered saline. The sections were then incubated with a rabbit antibody to ETS-1 (sc-350, Santa Cruz) or phosphorylated ETS-1 (44-1104G, Invitrogen), and antibodies to cell type–specific markers, including CD31 (ab32457, Abcam) for endothelium, synaptophysin (sc-21537, Santa Cruz) for podocytes, desmin (ab6322, Abcam) for mesangium, or CD68 (MCA341R, Serotec) for macrophages at 4°C overnight. The sections were then washed and incubated with the respective secondary antibodies conjugated with either Alexa Fluor 488 (green) or Alexa Fluor 594 (red; Invitrogen). Negative controls by omission of primary antibody were included in each experiment. Images were acquired using a Leica DM6000 epifluorescence microscope (Leica Microsystems, Bannockburn, IL) with a Hamamatsu ORCA ER cooled CCD camera and SimplePCI software (Compix, Inc, Cranberry Township, PA). Images were adjusted appropriately to remove background fluorescence.

Immunohistochemistry
The avidin–biotin–peroxidase immunohistochemical technique (ABC kit, Vector) was used to detect macrophage infiltration, using primary antibodies against CD68 as a specific marker for macrophages. After deparaffinization and heat-mediated antigen retrieval, CD68-positive areas were immunolocalized by incubation with respective primary antibody, followed by application of a biotinylated goat anti-rabbit secondary antibody (1:200) for 30 minutes. An observer unaware of the experimental conditions measured the number of CD68-positive cells (Image-Pro, Media Cybernetics, Bethesda, MD).

Morphometric Analysis for Glomerular Injury Score and Renal Fibrosis
Light microscopic pictures of Periodic Acid Schiff and trichrome stained kidney sections from the different experimental groups were used for morphometric analysis. Glomerular injury score (GIS) was measured in Periodic Acid Schiff–stained kidney sections by an experienced pathologist (H.F.) purposely blinded to the different experimental conditions and using a 0+ to 4+ scale as previously described. All glomeruli available in each slide (n=32–263) were analyzed. Renal fibrosis was evaluated blindly by the same pathologist in trichrome-stained kidney sections and expressed as percent of fibrosis in the interstitium.

Proteinuria
Proteinuria was measured by the Lowry method and adjusted for urine volume in the 24-hour collection (Cayman, Ann Arbor, MI). Urinary albumin concentrations were determined using a rat albumin ELISA quantitation kit from Bethyl (Montgomery, TX) and adjusted for urine volume obtained during the 24-hour collection period.

Urinary TGF-β1 and Angiotensinogen
Active TGF-β1 was measured in urine by ELISA (MB100B, R&D Systems, Minneapolis, MN) following the manufacturer’s instructions and adjusted for 24 hours urine volume. Urinary angiotensin was measured by ELISA as described previously and adjusted for 24 hours urine volume.

Renal Cortical Ang II
The cortical concentration of Ang II was measured by radioimmunoassay as previously described and expressed as fmol/g of total protein.

Statistical Analysis
Results were expressed as mean±SEM. The data were evaluated by 1-way or 2-way ANOVA. When the overall F test result of ANOVA was significant, a multiple-comparison Dunnett test was applied. Student t test was used in 2 mean comparisons. Differences were reported as significant when p value was < 0.05.

Results

Blood Pressure
DS rats fed a high-salt diet showed a progressive increase in blood pressure as assessed by radio-telemetry. As shown in Table, treatment with either DN or ARB resulted in modest albeit significant reductions in blood pressure. DS rats...
receiving concomitant treatment with ARB and DN did not increase blood pressure while on a high-salt diet and had blood pressures similar to those observed in rats receiving a normal-salt diet (Figure 1A). Neither treatment had a significant effect on heart rate as shown in Figure 1B.

**ETS-1 Expression Is Increased in Hypertensive DS Rats**

Hypertensive DS rats had increased glomerular expression of the phosphorylated form of ETS-1 compared with normotensive DS rats as assessed by Western blot (Figure 2A).

### Table. Effects of ETS-1 and Renin–Angiotensin System Blockade on Proteinuria, TGF-β, Angiotensinogen Urinary Excretion, and Cortical Angiotensin II

<table>
<thead>
<tr>
<th></th>
<th>NS</th>
<th>HS</th>
<th>HS/DN</th>
<th>HS/MU</th>
<th>HS/ARB</th>
<th>HS/DN/ARB</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Proteinuria, mg/24 h</strong></td>
<td>44.8±3.9</td>
<td>91.3±6.1*</td>
<td>65.3±6.6†</td>
<td>82.8±16.3*</td>
<td>51.9±3.2†</td>
<td>42.5±3.0†‡</td>
</tr>
<tr>
<td><strong>Albuminuria, mg/24 h</strong></td>
<td>3.7±1.1</td>
<td>56.4±17.2*</td>
<td>25.4±2.7†</td>
<td>36.0±10.5*</td>
<td>11.8±6.4†</td>
<td>11.6±1.8†</td>
</tr>
<tr>
<td><strong>Urinary TGF-β, pg/24 h</strong></td>
<td>13.0±8.8</td>
<td>417±87.6*</td>
<td>142.2±64.9†</td>
<td>498.3±138.3*</td>
<td>604.1±94.9*</td>
<td>23.0±9.3†‡</td>
</tr>
<tr>
<td><strong>Angiotensinogen, ng/24 h</strong></td>
<td>382.8±153</td>
<td>1105±148*</td>
<td>538.4±114†</td>
<td>812.2±372.9*</td>
<td>446±81.2†</td>
<td>330.2±116†</td>
</tr>
<tr>
<td><strong>Renal cortical angiotensin II, fmol/g</strong></td>
<td>1237±212</td>
<td>3197±675*</td>
<td>1008.6±127</td>
<td>1525.6±298†</td>
<td>927.2±204†</td>
<td>1352±397†</td>
</tr>
</tbody>
</table>

Data are presented as mean±SEM. ARB indicates angiotensin II receptor I blocker; DN, dominant negative peptide; ETS-1, transcription factor avian erythroblastosis virus E26 oncogen homolog-1; HS, high-salt diet; MU, mutant peptide; NS, normal-salt diet; and TGF-β, transforming growth factor-β.

*P<0.05 vs NS.
†P<0.05 vs HS.
‡P<0.05 vs HS/DN and HS/ARB.
No significant changes in the expression of total ETS-1 were observed in hypertensive DS rats compared with their normotensive counterparts. The expression of ETS-1 and phospho-ETS-1 was exclusively glomerular as assessed by immunofluorescence (Figure 2B). To determine the role of RAS activation on ETS-1 expression in hypertensive Dahl rats, we determined the effects of RAS blockade on ETS-1 expression. As shown in Figure 2C and 2D, the administration of the ARB candesartan significantly reduced the expression of the phosphorylated form of ETS-1 as assessed by western blot. In addition, the administration of the DN as well as the combination of the DN and ARB resulted in significant reductions in ETS-1 phosphorylation.

We performed colocalization studies to characterize the glomerular cells that express ETS-1 in hypertensive DS rats, using specific markers for vascular endothelium (CD31), mesangial cells (desmin), and podocytes (synaptopodin). As shown in Figure 3, in hypertensive DS rats, the expression of total ETS-1 partially colocalized with CD31 (Figure 3A–3C) indicating expression of ETS-1 in the glomerular endothelium. Following a similar strategy, we performed colocalization studies using synaptopodin as a podocyte marker, and we observed strong colocalization of ETS-1 with synaptopodin-expressing cells, indicating that podocytes express ETS-1 (Figure 3D–3F).

We also evaluated the expression of ETS-1 in the glomerular mesangium using desmin as a marker for mesangial expression. As shown in Figure 4, there was no clear colocalization of ETS-1 and desmin, suggesting that in vivo there is no significant expression of ETS-1 in the glomerular mesangium.

### ETS-1 Blockade Reduces Proteinuria in Hypertensive DS Rats

As others and we have shown, hypertensive DS rats had a significant increase in the urinary excretion of protein and albumin compared with normotensive DS rats (Table). Treatment with DN peptide but not MU resulted in significant reductions...
in both proteinuria and albuminuria. Treatment with ARB also resulted in significant reductions in protein excretion and albuminuria, while the combination of ARB and DN completely normalized the urinary excretion of protein in these rats but had no additional effect on albuminuria (Table).

ETS-1 Blockade Improves GIS and Interstitial Fibrosis

To assess the effect of ETS-1 blockade alone or in combination with RAS blockade on renal injury, we measured GIS in Periodic Acid Schiff–stained kidney sections and interstitial fibrosis in trichrome-stained sections. As expected, the GIS was significantly increased in hypertensive DS rats compared with normotensive DS rats (Figure 4). Treatment with DN, ARB, or DN/ARB, but not with MU, resulted in significant improvements in GIS (Figure 4). Similarly, we observed significant increases in interstitial fibrosis in hypertensive DS rats compared with normotensive DS rats (Figure 4). Treatment with DN or ARB alone resulted in a small and nonsignificant improvement in the severity of interstitial fibrosis. However, the combination of DN and ARB reduced interstitial fibrosis to levels similar to those seen in the control rats. Altogether, these findings suggest that RAS blockade and ETS-1 blockade alone improve GIS in hypertensive DS rats; however, only concomitant RAS and ETS-1 blockade had a significant effect on interstitial fibrosis.

ETS-1 Blockade Reduces Urinary TGF-β and Cortical Fibronectin Expression

To better assess the role of ETS-1 blockade alone or in combination with RAS blockade on renal injury, we determined their effects on cortical fibronectin expression and on urinary excretion of TGF-β. As shown in Figure 5, hypertensive DS rats had a significant increase in the cortical expression of fibronectin compared with normotensive DS rats. Treatment with DN, but not with MU, peptide normalized fibronectin expression as assessed by Western blot. Treatment with ARB, however, had no significant effect on fibronectin, whereas concomitant RAS and ETS-1 blockade had similar effects to ETS-1 blockade alone. To determine whether these changes in fibronectin expression were linked to changes in TGF-β production, a critical growth factor implicated in the pathogenesis of renal fibrosis, we measured the urinary excretion of TGF-β as we have and others have previously described.24 As shown in Table, hypertensive DS rats had significantly higher urinary excretion of TGF-β compared with normotensive DS rats. The administration of DN peptide resulted in significant reductions in the urinary excretion of TGF-β while treatment with the MU peptide had no effect. Treatment with ARB alone had no effect, whereas the combination of DN/ARB completely normalized the urinary excretion of TGF-β in hypertensive DS rats.

ETS-1 Blockade Reduces Macrophage Infiltration in Hypertensive DS rats

Given the well-known role of inflammation as mediator of the effects of renal injury in hypertensive DS rats,25,26 we determined the effects of ETS-1 blockade alone or in combination with RAS blockade on macrophage infiltration. As shown in Figure 6, we observed a significant increase in macrophage infiltration in hypertensive DS rats that was more evident in periglomerular...
areas and the cortical interstitium. Treatment with DN normalized the number of macrophages infiltrating the cortex of hypertensive DS rats while the MU peptide had no effect. Treatment with ARB had a modest albeit significant effect on macrophage infiltration while dual ETS-1 and RAS blockade reduced macrophage infiltration to levels similar to those of control rats on low-salt diet.

**Effects of ETS-1 Blockade on Components of the RAS**

To determine the effects of ETS 1 on specific components of the RAS, we determined the effects of ETS 1 blockade on the cortical concentrations of Ang II and the urinary excretion of angiotensinogen. As shown in the Table, hypertensive DS rats on a high-salt diet had a significant increase in the urinary excretion of angiotensinogen that was significantly reduced by ETS 1 blockade and ARB and normalized by the combination of ETS-1 and RAS blockade. Hypertensive DS rats had increased cortical expression of Ang II that was partially reduced by DN, MU, ARB, and concomitant ETS-1 and RAS blockade.

**Discussion**

ETS-1 is a member of the ETS family of transcription factors that share a highly conserved DNA-binding domain (ETS domain) that originates from the sequence described in the E26 avian erythroblastosis virus (E26 Transformation-specific Sequence). Studies in mutant mice have demonstrated that ETS-1 knockout animals have a lower number of glomeruli, and among the existing glomeruli, a higher number are immature, highlighting the important role of ETS-1 in the regulation of normal kidney development. The transcriptional activity of ETS-1 is modulated through post-translational modifications. Phosphorylation of threonine-38 increases the transcriptional activity of ETS-1 while calmodulin-dependent kinase II inhibits DNA binding through serine phosphorylation of ETS-1 inhibitory domains. ETS-1 is also regulated through nuclear transport via specific nuclear localization sequences that facilitate the movement of ETS-1 from the cytoplasm into the nucleus. The renal expression of ETS-1 is increased in a variety of models of renal injury. The anti-Thy1 model of glomerulonephritis is associated with a 4-fold increase in ETS-1 expression predominantly in the glomerular mesangium and at a lesser degree in podocytes and the glomerular endothelium. In rats with antiluminal basement–induced glomerulonephritis, there is also increased upregulation of ETS-1 in the glomeruli and in the interstitium, and in an ischemic model of acute renal failure, the tubular expression of ETS-1 is increased and associated with augmented expression of cyclin D, suggesting a role for ETS-1 in the control of tubular regeneration in acute kidney injury. In previous studies, we also demonstrated that Ang II increases the cortical expression of ETS-1 in Sprague-Dawley rats and that knockdown of ETS-1 reduces Ang II-stimulated fibronectin production in rat mesangial cells. In other studies, we demonstrated that Ang II increases the glomerular expression of ETS-1 in mice and that blockade of ETS-1 using a specific DN reduces proteinuria, inflammation, and fibrosis induced by Ang II. Importantly, in these studies, ETS-1 blockade did not
reduce blood pressure, suggesting that hemodynamic effects did not mediate the beneficial actions of ETS-1 blockade.

In the present studies, we have demonstrated increased glomerular expression of ETS-1 in hypertensive Dahl/Rapp salt-sensitive rats, a paradigm of salt-sensitive hypertension in humans. We demonstrated that hypertensive Dahl/Rapp salt-sensitive rats have a significant increase in the expression of the phosphorylated (T38) form of ETS-1 without significant changes in the expression of total ETS-1. Although we did not observe changes in the expression of total ETS-1, we cannot rule out that changes in the expression of total ETS-1 may occur at other time points. Using colocalization methods, we demonstrated that the expression of ETS-1 is mostly glomerular and predominantly expressed in the glomerular epithelium and to a lesser degree in the glomerular endothelium.

Several studies have demonstrated that DS rats when fed a high-salt diet and made hypertensive have increased local activation of the RAS, characterized by sustained levels of Ang II, increased levels of angiotensinogen, and increased expression of the AT1 receptor.14 In addition, as others and we have shown, salt-sensitive hypertension is associated with reduced nitric oxide bioavailability and increased reactive oxygen species production.2,39,40 In support of the role for increased RAS activation in salt-sensitive hypertension, AT1 receptor blockade ameliorates cardiac or renal dysfunction in these rats, suggesting an important role for RAS in the development of end-organ injury in salt-sensitive hypertension.15,16 In the current studies, we observed increased expression of the phosphorylated form of ETS-1 in hypertensive DS rats that was significantly reduced by RAS blockade with ARB, suggesting that increased RAS activation mediates increased ETS-1 phosphorylation and activation in hypertensive DS rats. To determine the role of ETS-1 in the pathogenesis of renal injury in salt-sensitive hypertension, we used a DN ETS-1 peptide that competes for DNA binding with ETS-1 but does not initiate gene transcription. In our studies, we observed that ETS-1 blockade reduced ETS-1 phosphorylation at T38; these findings are consistent with a positive feedback of ETS-1 but does not initiate gene transcription. In our studies, we cannot observe changes in the expression of total ETS-1, we cannot rule out that changes in the expression of total ETS-1 may occur at other time points. Using colocalization methods, we demonstrated that the expression of ETS-1 is mostly glomerular and predominantly expressed in the glomerular epithelium and to a lesser degree in the glomerular endothelium.

ETS-1 blockade resulted in significant reductions in GIS, fibronectin expression, proteinuria, and macrophage infiltration but had no significant effect on interstitial fibrosis. RAS blockade also reduced GIS, proteinuria, and macrophage infiltration and had a no significant effect on fibronectin or fibrosis. By contrast, concomitant ETS-1 and RAS blockade had additive effects on all parameters examined. In addition, we observed that ETS-1 blockade resulted in a significant reduction in the urinary excretion of TGF-β, suggesting that ETS-1 may be a direct regulator of TGF-β in hypertensive DS rats. By contrast, RAS blockade did not modify the urinary excretion of TGF-β, indicating that other pathways independent of RAS participated in the production of TGF-β in hypertensive DS rats. Both ETS-1 blockade and RAS blockade had small effects on blood pressure as measured by radio-telemetry; however, rats with ETS-1 and RAS blockade had blood pressures that were similar to those from rats on a normal-salt diet, indicating that ETS-1 may also be playing a role in blood pressure regulation either directly or indirectly. In addition, these findings suggest that the additional beneficial effects of concomitant ETS-1 and RAS blockade are in large part due to their effects on blood pressure.

To better understand the interaction between RAS and ETS-1, we measured the expression of some of the main components of RAS in the different experimental groups. As previously shown by us and others, hypertensive DS rats had significant increases in the urinary excretion of angiotensinogen and intrarenal concentration of Ang II indicative of increased RAS activation. Both ETS-1 and RAS blockade induced significant reductions in the urinary excretion of angiotensinogen and tissue levels of Ang II. In addition, concomitant ETS-1 and RAS blockade further reduced the urinary excretion of angiotensinogen. These findings suggest that ETS-1 also plays a role in the regulation of the RAS, the mechanisms by which ETS-1 could be modulating RAS activity are unclear and are the subject of active investigation in our laboratory.

**Perspective**

In these studies, we have unveiled the role of the transcription factor ETS-1 as a mediator of renal injury in salt-sensitive hypertension. In addition, we determined that the activation of RAS mediates ETS-1 phosphorylation in hypertensive salt-sensitive rats and that concomitant RAS and ETS-1 blockade have beneficial additive effects on renal injury, suggesting that concomitant blockade of RAS and ETS-1 could be a novel therapeutic strategy for the treatment and prevention of end-organ injury in hypertension.

**Acknowledgments**

We are grateful for the support of Core Facilities at the O’Brien Kidney Center at the University of Alabama at Birmingham.

**Sources of Funding**

A Merit Review Award (E.A. Jaimes), a Research Grant (1 IP1 BX001595; P.W. Sanders and E.A. Jaimes) from the Office of Research and Development, Medical Research Service, Department of Veterans Affairs, and a Byrne Fund Grant (E.A. Jaimes) from Memorial Sloan Kettering Cancer Center funded these studies.

**Disclosures**

None.

**References**


Novelty and Significance

What Is New?

- These studies demonstrate increased expression of the transcription factor avian erythroblastosis virus E26 oncogen homolog-1 (ETS-1) in salt-sensitive hypertension.
- Blockade of ETS-1 reduces renal injury in salt-sensitive hypertension.

What Is Relevant?

- These studies unveil a potential target for the treatment and prevention of end-organ injury in hypertension.

Summary

- Expression of the phosphorylated form of ETS-1 is increased in glomeruli from hypertensive Dahl salt-sensitive rats.
- ETS-1 and renin-angiotensin system blockade have additive beneficial effects in salt-sensitive hypertension by reducing proteinuria, glomerular injury score, interstitial fibrosis, fibroepithelial crescent formation, and transforming growth factor-β excretion.
Transcription Factor Avian Erythroblastosis Virus E26 Oncogen Homolog-1 Is a Novel Mediator of Renal Injury in Salt-Sensitive Hypertension
Wenguang Feng, Phillip Chumley, Minolta C. Prieto, Kayoko Miyada, Dale M. Seth, Huma Fatima, Ping Hua, Gabriel Rezonzew, Paul W. Sanders and Edgar A. Jaimes

Hypertension. published online January 26, 2015;
Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2015 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/early/2015/01/23/HYPERTENSIONAHA.114.04533

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/